Good
Mostly Aligned
Patient Risk:
Low
Summary
Most mechanistic and interaction claims (including grapefruit juice increasing atorvastatin plasma concentrations and dose-related concern with strong CYP3A4 inhibitors) are consistent with the provided Lipitor label excerpts. A few statements are more specific than the excerpts support (e.g., exact “up to 50%” increase; specific effects of orange/lemon/tangerine/other citrus beyond grapefruit).
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication.
Consistent with label excerpts describing LIPITOR as a statin class drug (e.g., Warnings discuss “other statins” and statin-related effects).
Increased atorvastatin levels in the bloodstream can potentially cause adverse effects.
Supported generally by the label’s warnings/precautions that increased exposure from concomitant CYP3A4 inhibitors can increase plasma concentrations of atorvastatin, and by statements that atorvastatin therapy is associated with adverse reactions and that concomitant administration can increase risk of myopathy/rhabdomyolysis.
Grapefruit juice can increase the bioavailability of atorvastatin by up to 50%.
Partially supported: label states grapefruit juice can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (>1.2 liters per day), but the provided excerpts do not show the “up to 50%” figure.
Consuming grapefruit juice while taking Lipitor can lead to higher levels of the medication in the bloodstream.
Label 7.2 Grapefruit Juice: contains components that inhibit CYP3A4 and can increase plasma concentrations of atorvastatin.
Other citrus fruits may still interact with Lipitor.
Not directly stated in the provided excerpts; however, label specifically addresses grapefruit juice and CYP3A4 inhibition as a mechanism, while not restricting interactions to only grapefruit.
Unsupported Statements
Lipitor works by reducing the production of low-density lipoprotein (LDL) cholesterol in the liver.
No mechanism-of-action statement about reducing LDL production in the liver is present in the provided label excerpts.
Lipitor inhibits the enzyme HMG-CoA reductase.
No statement in the provided label excerpts explicitly identifying HMG-CoA reductase inhibition.
Citrus fruits contain furanocoumarins.
No furanocoumarin content statement appears in the provided label excerpts.
Furanocoumarins in citrus fruits can interact with certain medications, including Lipitor.
No furanocoumarin-specific interaction statement appears in the provided label excerpts.
Citrus fruit interactions can lead to increased levels of atorvastatin in the bloodstream.
Label excerpt specifically addresses grapefruit juice; the broader “citrus fruits” claim beyond grapefruit is not supported by the provided excerpts.
Grapefruit juice can increase the bioavailability of atorvastatin by up to 50%.
The provided excerpts do not include a “50%” value.
Orange juice does not significantly affect the bioavailability of atorvastatin.
No orange juice claim is present in the provided label excerpts.
Lemon juice does not significantly affect the bioavailability of atorvastatin.
No lemon juice claim is present in the provided label excerpts.
Tangerine juice can increase the bioavailability of atorvastatin.
No tangerine juice claim is present in the provided label excerpts.
More research is needed to fully understand interactions between Lipitor and other citrus fruits.
No statement about ongoing research/uncertainty is present in the provided label excerpts.
Contradictions
Important Omissions
The label’s condition/threshold for grapefruit juice (“especially with excessive grapefruit juice consumption (>1.2 liters per day)”) and that the effect is tied to CYP3A4 inhibition by grapefruit components.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The core safety-relevant message supported by the label (grapefruit juice can increase atorvastatin plasma concentrations via CYP3A4 inhibition) is included. However, several broader-than-label citrus fruit claims and an unsupported numeric magnitude (“up to 50%”) could overgeneralize risk.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several interaction claims extend beyond grapefruit juice and include unsupported specificity (furanocoumarins; orange/lemon/tangerine effects; “up to 50%”).
Suggested Improvement
Limit citrus interaction claims to grapefruit juice as specified, and avoid unsupported mechanistic and quantitative statements not present in the provided label excerpts.